I
130.14
-0.93 (-0.71%)
| Previous Close | 131.07 |
| Open | 131.19 |
| Volume | 469,697 |
| Avg. Volume (3M) | 1,484,887 |
| Market Cap | 10,341,484,544 |
| Price / Earnings (TTM) | 14.19 |
| Price / Earnings (Forward) | 10.80 |
| Price / Sales | 1.47 |
| Price / Book | 1.23 |
| 52 Weeks Range | |
| Earnings Date | 22 Jul 2025 - 28 Jul 2025 |
| Profit Margin | 9.26% |
| Operating Margin (TTM) | 13.21% |
| Diluted EPS (TTM) | 9.18 |
| Quarterly Revenue Growth (YOY) | -4.30% |
| Quarterly Earnings Growth (YOY) | -17.80% |
| Total Debt/Equity (MRQ) | 37.84% |
| Current Ratio (MRQ) | 1.27 |
| Operating Cash Flow (TTM) | 1.23 B |
| Levered Free Cash Flow (TTM) | 1.00 B |
| Return on Assets (TTM) | 4.41% |
| Return on Equity (TTM) | 8.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | ICON plc | Bearish | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 100.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bluespruce Investments, Lp | 31 Dec 2024 | 1,223,117 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 215.00 (Citigroup, 65.21%) | Buy |
| Median | 160.00 (22.95%) | |
| Low | 150.00 (JP Morgan, 15.26%) | Hold |
| Average | 172.25 (32.36%) | |
| Total | 3 Buy, 5 Hold | |
| Avg. Price @ Call | 143.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 15 May 2025 | 173.00 (32.93%) | Buy | 130.66 |
| 09 Apr 2025 | 200.00 (53.68%) | Buy | 155.49 | |
| Baird | 02 May 2025 | 160.00 (22.94%) | Hold | 142.96 |
| Barclays | 02 May 2025 | 155.00 (19.10%) | Hold | 142.96 |
| 10 Apr 2025 | 165.00 (26.79%) | Hold | 142.64 | |
| Goldman Sachs | 02 May 2025 | 160.00 (22.94%) | Hold | 142.96 |
| JP Morgan | 29 Apr 2025 | 150.00 (15.26%) | Hold | 149.31 |
| TD Cowen | 14 Apr 2025 | 157.00 (20.64%) | Hold | 146.74 |
| Truist Securities | 10 Apr 2025 | 208.00 (59.83%) | Buy | 142.64 |
| Citigroup | 07 Apr 2025 | 215.00 (65.21%) | Buy | 150.83 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | ICON plc Schedules Second Quarter 2025 Earnings Conference Call |
| 19 May 2025 | Announcement | ICON releases its ICON Cares 2024 Report |
| 07 May 2025 | Announcement | Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies |
| 30 Apr 2025 | Announcement | ICON Reports First Quarter 2025 Results |
| 02 Apr 2025 | Announcement | ICON PLC: BFA Law has Filed an Expanded Securities Fraud Class Action Lawsuit Against ICON plc (NASDAQ:ICLR) |
| 31 Mar 2025 | Announcement | ICON plc Schedules First Quarter 2025 Earnings Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |